-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 18, 2021, Ipsen and Accent Therapeutics announced that they have reached an exclusive global cooperation agreement to advance the research, development, manufacturing and commercialization of drugs targeting the RNA-modified protein METTL3
.
Accent's new METL3 small molecule inhibitor is designed to treat specific subtypes of acute myeloid leukemia (AML) with high unmet medical needs
AML is a difficult-to-treat blood and bone marrow cancer.
Globally, the incidence of AML has been increasing year by year in the past 20 years
.
RNA-modifying proteins (RMPs) are a class of emerging targets that represent a new strategy for the treatment of various cancers
One of the most common modifications of mRNA is the methylation of the N6 adenine base to form N6-methyladenosine (m6A)
.
The methyltransferase complex METL3/METTL14 catalyzes this modification process
Image source: Accent's official website
According to the terms of the cooperation agreement, Ipsen obtained the exclusive development rights for a METL3 small molecule inhibitor
.
Accent may receive a total of US$446 million in advance payments, preclinical, clinical, regulatory and sales milestone payments, plus future royalties for tiered sales of the product
Reference materials:
[1] Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3.
(The original text has been deleted)
